By Andrew Silver SHANGHAI (Reuters) -Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its ...

Should you invest $1,000 in Amazon right now? Before you buy stock in Amazon, consider this: The Motley Fool Stock Advisor ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...

Proponents say direct-to-consumer sales by drugmakers cut out intermediaries that add needlessly to prices. Detractors see ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Hims & Hers stands out for personalized, compounded medications and consistent margin expansion but faces rising risks tied ...

Anthropic's Scott White explains how AI agents evolved from chatbots to autonomous workers at VentureBeat Transform 2025, cutting enterprise tasks from weeks to minutes.